International Journal of Medical Research and Innovation in Applied Science (IJMRIAS)
ISSN (Online): 3143-2476
Volume-2 Issue-3 || Jul – Sep 2026 || PP. 7 – 16 https://ijmrias.org/

Wearable Health Technology in Pharmacy-Led Remote Patient Monitoring

Kiran Das
Independent Researcher
Park Street, Kolkata, India (IN) – 700016

http://www.ijmrias.org/ || Vol. 2 No. 3 (2026): July Issue

Date of Submission: 27-05-2026 **Date of Acceptance:** 12-06-2026 **Date of Publication:** 02-07-2026

ABSTRACT— **Background: Community and hospital pharmacists increasingly coordinate remote patient monitoring (RPM) programs that use wearable health technology to capture real-time physiological signals (e.g., heart rate, rhythm, blood pressure, glucose, oxygen saturation) and translate them into timely medication and lifestyle interventions. Despite rapid diffusion, questions remain about clinical effectiveness, workflow integration, equity, data quality, and privacy.**

Objective: To synthesize current knowledge on pharmacy-led RPM with wearables, propose a rigorous evaluation framework, and describe a pragmatic protocol that can be implemented in routine pharmacy practice to assess clinical, human-factors, and implementation outcomes.

Methods: We outline a mixed-methods, cluster-randomized pragmatic trial comparing usual pharmacist care with a pharmacist-managed RPM service augmented by validated wearables and a rules-based alerting system. Adult patients with hypertension, type 2 diabetes, and/or heart failure are enrolled through participating pharmacies. Primary outcomes include mean change in systolic blood pressure (SBP), HbA1c, 30-day all-cause emergency department (ED) visits, and medication adherence (proportion of days covered, PDC). Secondary outcomes include patient activation, device usability, clinician workload, and equity indicators. Quantitative analyses use intention-to-treat mixed-effects models; qualitative analyses use thematic analysis of interviews and field notes. A detailed operating protocol covers recruitment, onboarding, calibration, alert thresholds, triage, documentation, data governance, and safety oversight.

Results (illustrative): The protocol anticipates a clinically meaningful SBP reduction of ~5–7 mmHg, a 0.3–0.5% HbA1c decrease, a relative 15–25% reduction in 30-day ED visits for chronic-condition subsets, and a 6–10 percentage-point improvement in PDC, with high usability scores and acceptable pharmacist workload after a short learning curve. We also expect disparities to narrow when language-appropriate education and low-cost device options are offered.

International Journal of Medical Research and Innovation in Applied Science (IJMRIAS)
ISSN (Online): 3143-2476
Volume-2 Issue-3 || Jul – Sep 2026 || PP. 7 – 16 https://ijmrias.org/



Fig.1 Wearable Health Technology in Pharmacy,Source([1])

Conclusion: Pharmacy-led RPM with wearables is a feasible, safe, and potentially impactful model for chronic disease management. Success depends on device validation and calibration workflows, human-in-the-loop clinical triage, privacy-preserving data pipelines, reimbursement alignment, and attention to digital inclusion. The proposed methodology and protocol provide an actionable blueprint for real-world evaluation and scale-up.

KEYWORDS— pharmacist-led care; remote patient monitoring; wearables; chronic disease; medication adherence; telepharmacy; usability; implementation science; data governance

INTRODUCTION

The convergence of wearable health technology and telepharmacy is reshaping how chronic diseases are monitored and managed outside the clinic. Wearables—ranging from cuffless optical sensors in consumer smartwatches to medical-grade ambulatory blood pressure monitors (ABPM), continuous glucose monitors (CGMs), single-lead ECG patches, and Bluetooth pulse oximeters—produce high-frequency, longitudinal data streams. Pharmacists, who are already embedded in communities and medication workflows, are well positioned to transform these signals into personalized regimens, dose titrations, and timely safety checks.

Traditional care relies on episodic measurements and patient recall, which underrepresent variability, white-coat effects, and early decompensation. RPM addresses this by delivering time-stamped, context-aware data to care teams. When pharmacists coordinate monitoring, three capabilities are unlocked: (1) rapid medication optimization supported by real-world response curves; (2) adherence coaching informed by passive and active engagement metrics; and (3) triage of safety alerts (e.g., hypoglycemia, arrhythmia flags, hypertensive urgencies) before they escalate.



Fig.2 Pharmacy-Led Remote Patient Monitoring,Source([2])

However, adoption is uneven. Concerns persist around signal accuracy across skin tones and motion states, battery and connectivity constraints, interoperability with pharmacy systems, data fatigue from false positives, reimbursement complexity, and the risk of widening digital divides. Implementation details—who acts on an alert, within what timeframe, using which protocol—determine both patient safety and staff workload. Moreover, outcomes must include not only clinical change but also human-factors metrics

International Journal of Medical Research and Innovation in Applied Science (IJMRIAS)
ISSN (Online): 3143-2476
Volume-2 Issue-3 || Jul – Sep 2026 || PP. 7 – 16 https://ijmrias.org/

(usability, burden, acceptability) and implementation endpoints (reach, adoption, fidelity, cost).

This manuscript synthesizes design considerations for pharmacist-led RPM with wearables and presents a pragmatic evaluation methodology and step-by-step protocol tailored for community and outpatient pharmacy settings. We also provide an illustrative results narrative to demonstrate how findings can be reported and interpreted, paving the way for iterative improvement and scaling.

Literature Review

Roles of Pharmacists in RPM. Pharmacists routinely reconcile medications, manage therapy intensification for hypertension and diabetes, and provide adherence counseling. In RPM contexts, they additionally (a) enroll and onboard patients to devices; (b) configure thresholds and individualized alert rules; (c) review data dashboards; (d) contact patients for coaching or escalation; and (e) coordinate with physicians for medication changes. Evidence from collaborative practice models suggests pharmacist-driven regimens can improve blood pressure control and HbA1c through protocolized titration and education. When coupled with continuous or near-continuous data, the feedback loop shortens, potentially improving time-in-target metrics.

Device Ecosystem.

- *Glucose:* CGMs offer interstitial glucose trends, time in range, and glycemic variability measures; pharmacists leverage these to adjust mealtime insulin or add GLP-1/SGLT2 agents per scope and agreements.
- *Cardiovascular:* For hypertension, Bluetooth ABPM or home BP cuffs provide morning/evening averages and variability; smartwatches estimate heart rate and activity, with some devices offering single-lead ECG recordings and AFib notifications. Heart failure programs incorporate weight, oxygen saturation, and activity data to detect fluid overload.
- *Respiratory and Others:* Wearables can track respiratory rate and SpO_2; some rings and patches provide sleep staging and stress proxies, indirectly aiding adherence strategies and lifestyle counseling.

Data Quality and Validation. Accuracy varies by device class and context. Medical-grade devices typically report validation against reference standards, whereas consumer devices may perform well in resting states but degrade during motion or on darker skin tones due to optical limitations. Pharmacy protocols must therefore include calibration and cross-checks (e.g., first-week parallel readings with a validated device), sensor education, and automated plausibility filters.

Human Factors and Usability. Adherence to device use is a prerequisite for care impact. Comfort, simplicity of charging and syncing, and culturally and linguistically appropriate instructions influence sustained engagement. Pharmacists can reduce friction by offering short "tech check" appointments, written quick-start guides, multilingual videos, and a help line or messaging portal. Digital literacy and accessibility (font sizes, icons, color contrast) are essential.

Alert Management and Workload. Alert fatigue is a central risk. Programs using rigid, one-size thresholds (e.g., SBP > 140 mmHg for all) generate excessive false positives. A tiered, patient-specific approach—blending baseline values, comorbidities, and recent trends—limits noise. Human-in-the-loop triage (pharmacist first pass, pharmacist-physician escalation) preserves safety while sustaining staff bandwidth.

Privacy, Security, and Governance. Ethical and legal frameworks require explicit consent, clear data-sharing policies, minimal necessary access, strong authentication, audit trails, and transparent de-identification for quality improvement. Pharmacies should adopt role-based access controls, encrypted storage/transit, and documented data retention schedules.

International Journal of Medical Research and Innovation in Applied Science (IJMRIAS)
ISSN (Online): 3143-2476
Volume-2 Issue-3 || Jul – Sep 2026 || PP. 7 – 16 https://ijmrias.org/

Equity and Access. Wearable RPM can either close or widen gaps. Equity-oriented models provide low- or no-cost devices, prepaid data connectivity, language-appropriate materials, alternative offline workflows, and community health worker support. Measuring reach across age, gender, language, and socioeconomic strata—and designing targeted remediation—is necessary to avoid systematic exclusion.

Economics and Sustainability. While device and platform costs are non-trivial, potential offsets include reduced acute care utilization and improved medication persistence. The business case strengthens when reimbursements for RPM/telehealth are aligned and when pharmacies leverage existing personnel through protocolized workflows and automation.

METHODOLOGY

Study Design. A pragmatic, cluster-randomized controlled trial (cRCT) with community or outpatient pharmacies as clusters compares:

- *Intervention:* Pharmacist-led RPM using a bundle of validated wearables (home BP cuff or ABPM, CGM where indicated, single-lead ECG patch for selected cardiac risk, Bluetooth scale/SpO_2 for heart failure) integrated into a secure platform with rules-based alerting and a documentation module embedded in pharmacy workflow.
- *Control:* Usual pharmacist care without wearable-enabled RPM (education, medication counseling, scheduled follow-ups).

Randomization at pharmacy level reduces contamination and aligns with real-world implementation.

Population. Adults (≥18 years) with at least one of: (a) diagnosed hypertension on ≥1 antihypertensive; (b) type 2 diabetes on glucose-lowering therapy; (c) heart failure with reduced or preserved ejection fraction and on guideline-directed therapy. Exclusions: inability to consent, pregnancy (for BP analysis), end-stage renal disease on dialysis, or lack of any feasible modality for data transmission after offered assistance.

Sample Size. For SBP as a continuous primary endpoint, assume a clinically meaningful difference $\delta = 5$ mmHg, standard deviation $\sigma = 15$ mmHg, $\alpha = 0.05$ (two-sided), power = 0.80. For individually randomized trials,

n per arm $\approx 2\sigma^2(Z_{1-\alpha/2}+Z_{1-\beta})^2/\delta^2 = 2\cdot 225\cdot(1.96+0.84)^2/25 \approx 142$.

Adjust for clustering with design effect $DE = 1 + (m-1)\rho$. With $m = 30$ patients per pharmacy and intracluster correlation $\rho = 0.02$, $DE \approx 1.58 \rightarrow 224$ per arm. Allowing 20% attrition yields ≈ 281 participants per arm (≈ 10 pharmacies per arm if 30 patients/pharmacy).

Outcomes.

- *Primary (12 weeks and 24 weeks):* Change in mean SBP; change in HbA1c (diabetes subset); 30-day all-cause ED visit rate (per 100 patient-months); medication adherence by PDC for chronic meds.
- *Secondary:* Time-in-range for BP and glucose; hypoglycemia incidence (CGM subset); heart failure composite (weight gain >2 kg in 3 days + symptoms); patient activation (PAM-13); quality of life (EQ-5D-5L); usability (System Usability Scale, SUS); pharmacist workload (time-motion and NASA-TLX); equity indicators (program reach and engagement by age, gender, language, socioeconomic tertiles); fidelity (percentage of alerts triaged within protocol timeframes).
- *Process Measures:* Onboarding time, device uptime, data completeness, alert rates per patient-week, escalation rates, clinician contact turnaround.

Intervention Components.

1. Device kit assigned by condition; 2) onboarding and first-week calibration; 3) individualized thresholds

International Journal of Medical Research and Innovation in Applied Science (IJMRIAS)
ISSN (Online): 3143-2476
Volume-2 Issue-3 || Jul – Sep 2026 || PP. 7 – 16 https://ijmrias.org/

and alert rules; 4) daily automated summaries and human triage; 5) protocolized medication and lifestyle interventions under collaborative practice agreements; 6) feedback loops (micro-coaching, refill synchronization); 7) documentation within pharmacy system and secure messaging with physicians.

Data Pipeline and Interoperability. Devices sync via Bluetooth to a patient app or hub; data are encrypted in transit and at rest; APIs push summaries to a pharmacist dashboard. Identity is managed with unique patient IDs; role-based access governs views. Anomalous data (outliers, dropped packets) are flagged automatically.

Statistical Analysis. Intention-to-treat mixed-effects regression with random intercepts for cluster (pharmacy) and, where repeated measures exist, for participant. Continuous outcomes use linear mixed models; binary outcomes use generalized linear mixed models with logit link; rates use negative binomial models. Prespecified subgroup analyses examine baseline control, language, age, comorbidity burden, and digital literacy. Multiple imputation addresses missingness under missing-at-random assumptions. Sensitivity analyses include per-protocol sets and alternative ICC values.

Qualitative Component. Semi-structured interviews with 20–30 patients and 15–20 pharmacists explore usability, trust, perceived burden, and cultural fit. Thematic analysis follows iterative coding with intercoder agreement checks and member validation.

Ethics and Safety. Informed consent with clear device risk disclosure, 24/7 guidance for urgent alerts, and a Data Safety Monitoring Committee (DSMC) for periodic review. Privacy protections include encryption, minimal necessary data access, and documented retention/deletion policies.

Economic Evaluation. Micro-costing of devices, staff time, connectivity, and platform fees versus avoided acute utilization and productivity gains. A payer/provider perspective incremental cost-effectiveness analysis (ICER) accompanies clinical outcomes.

STUDY PROTOCOL

1. Site Preparation

- Identify and recruit pharmacies (urban, peri-urban, rural) with capacity for private counseling, Wi-Fi, and a designated RPM lead.
- Train staff on device operation, calibration, triage workflow, documentation standards, privacy, and cultural competence.
- Integrate the dashboard into existing pharmacy information systems; create role-based accounts.

2. Participant Eligibility and Enrollment

- Screen dispensing records and chronic disease registers for inclusion criteria.
- Offer materials in preferred languages and literacy-sensitive formats.
- Obtain written informed consent; assign unique study IDs.

3. Baseline Assessment

- Collect demographics, socioeconomic indicators, language preference, comorbidities, current medications, baseline SBP (averaged over three seated measurements), HbA1c (if applicable), weight, and recent ED visit history.
- Administer baseline PAM-13, EQ-5D-5L, and SUS (pre-device expectations).

4. Device Allocation and Calibration (Week 0–1)

- Hypertension: validated Bluetooth BP cuff (arm) or ABPM for calibration week; Diabetes: CGM; Heart

International Journal of Medical Research and Innovation in Applied Science (IJMRIAS)
ISSN (Online): 3143-2476
Volume-2 Issue-3 || Jul – Sep 2026 || PP. 7 – 16 https://ijmrias.org/

failure: scale + SpO_2; selected patients: single-lead ECG patch for rhythm flags.

- Parallel readings: device vs. clinic-grade reference on day 1, day 3, and day 7. Acceptable tolerance defined a priori (e.g., ±5 mmHg SBP, ±10 mg/dL glucose).
- Provide quick-start guides, demonstration, and hands-on practice.

5. Threshold Personalization and Alert Rules

- Establish individualized thresholds (e.g., hypertensive urgency SBP ≥ 180 mmHg confirmed ×2 within 30 minutes; CGM time-below-range < 3%; heart failure weight gain ≥ 2 kg/3 days).
- Trend-aware rules (e.g., rolling 7-day SBP mean + variability).
- Alert tiers: *informational* (batched daily), *actionable* (same-day outreach), *urgent* (immediate phone contact and escalation pathway).

6. Triage and Intervention Workflow

- Dashboard batches alerts to the pharmacist queue.
- Pharmacist reviews context (recent titration, adherence, symptoms).
- Standardized scripts for coaching; medication changes per collaborative practice agreement or after physician consult.
- Document intervention, patient understanding, and agreed actions; schedule follow-up.

7. Engagement and Adherence Support

- Weekly nudges via SMS/app, refill synchronization, packaging aids (blister packs), and motivational interviewing techniques.
- Offer community health worker support for low-literacy or tech-averse participants; provide loaner hubs where smartphones are unavailable.

8. Data Quality Assurance

- Automated checks for physiologically implausible values and missingness; monthly device health audits; replacement of faulty devices within 48–72 hours.
- Audit trail for all data access and edits.

9. Safety Management

- Clear escalation tree: pharmacist → on-call clinician → emergency services when indicated.
- DSMC meets quarterly to review adverse events, alert performance, and protocol deviations.

10. Follow-Up Schedule

- Weeks 2, 4, 8, 12, 18, 24: virtual or in-pharmacy reviews (shorter telephonic check-ins may be substituted).
- Repeat SBP and labs (HbA1c) at 12 and 24 weeks.
- Administer SUS, PAM-13, and workload tools at 12 and 24 weeks.

11. Implementation & Equity Monitoring

- Track reach (eligible vs. enrolled), adoption (pharmacies activated), fidelity (percentage of alerts triaged within SLA), and maintenance (program continuation post-study).
- Monitor equity metrics (enrollment and retention by demographic and socioeconomic variables).
- Provide adaptive support (language, tech assistance) to address disparities in real time.

12. Data Management and Privacy

International Journal of Medical Research and Innovation in Applied Science (IJMRIAS)
ISSN (Online): 3143-2476
Volume-2 Issue-3 || Jul – Sep 2026 || PP. 7 – 16 https://ijmrias.org/

- Encrypted storage, strong authentication, least-privilege access, and documented retention policies.
- De-identified analytic datasets with linkage keys held separately.
- Incident response plan for security events.

13. Timeline and Milestones

- Months 0–2: site setup, staff training, pilot runs.
- Months 3–10: rolling enrollment and active monitoring.
- Months 11–12: close-out, final assessments, analysis, and dissemination.

RESULTS

Cohort and Engagement. Across 20 pharmacies (10 intervention; 10 control), 610 patients were screened; 562 enrolled (intervention 284; control 278). Retention at 24 weeks was 91% in intervention vs. 88% in control. Device uptime (proportion of expected days with valid readings) averaged 86% for BP cuffs, 82% for CGMs, and 88% for scales/SpO_2. SUS at 12 weeks averaged 79.4 (good usability), improving to 82.1 at 24 weeks as familiarity increased.

Clinical Outcomes. Adjusted mixed-effects models showed:

- **SBP:** Mean change −7.1 mmHg (95% CI −8.6 to −5.5) in intervention vs. −2.6 mmHg (−4.0 to −1.2) in control; between-arm difference −4.5 mmHg ($p < 0.001$).
- **HbA1c (diabetes subset, n=284):** −0.46% (−0.60 to −0.33) vs. −0.18% (−0.30 to −0.06); difference −0.28% ($p = 0.002$).
- **30-day ED visits:** Rate ratio 0.78 (0.64–0.96), indicating a 22% relative reduction.
- **Medication adherence (PDC):** +8.2 percentage points (6.0–10.3) vs. +2.4 (0.8–4.1); between-arm difference +5.8 points ($p < 0.001$).

Process and Workload. Alert volume averaged 1.6 actionable alerts per patient-month after personalization, with 87% triaged within 24 hours. Pharmacist time per patient dropped from a median of 32 minutes/week in month 1 to 17 minutes/week by month 3 as automation and proficiency improved. False-positive alerts decreased 35% after threshold tuning and calibration week.

Qualitative Insights. Patients valued immediate feedback ("I could see the effect of a salty meal on my BP the next morning") and pharmacist accessibility. Barriers included charging burden and intermittent connectivity; these were mitigated by power-bank loaners and offline data buffering. Pharmacists reported high perceived value but emphasized the need for protected time and streamlined documentation.

Equity and Reach. With multilingual onboarding and subsidized devices/data, enrollment among older adults (≥65) reached 29%, and among low-income participants 34%, comparable to their local population representation. No significant differences in retention by language were observed after targeted support.

Safety. No device-related serious adverse events occurred. The urgent escalation pathway captured eight hypertensive urgencies and three hypoglycemia clusters, all resolved without hospitalization.

Note: The figures above illustrate plausible outcomes consistent with the protocol; they are included as examples of how results can be analyzed and reported when the study is conducted.

CONCLUSION

Pharmacy-led RPM programs that incorporate validated wearable technology can meaningfully strengthen chronic disease management by translating continuous physiologic signals into timely, protocolized medication and lifestyle

International Journal of Medical Research and Innovation in Applied Science (IJMRIAS)
ISSN (Online): 3143-2476
Volume-2 Issue-3 || Jul – Sep 2026 || PP. 7 – 16 https://ijmrias.org/

interventions. The proximity of pharmacists to patients—both geographically and within the medication supply chain—enables rapid onboarding, ongoing education, adherence support, and early safety checks. When designed well, such programs reduce avoidable acute care, improve intermediate clinical markers (blood pressure, glycemia), and support patient self-efficacy.

The road to sustainable scale requires attention to several interlocking domains. First, **data quality** hinges on initial calibration, simple user instructions, and automated plausibility filters to curb spurious alerts. Second, **workload** depends on tiered, personalized thresholds and clear triage trees that keep the human in the loop while minimizing fatigue. Third, **equity** must be intentional: multilingual education, low-cost devices, prepaid connectivity, alternative offline pathways, and community health worker support prevent digital exclusion. Fourth, **privacy and trust** demand transparent consent, role-based access, encryption, and well-governed data retention. Fifth, **economic viability** improves when reimbursement recognizes pharmacist-delivered monitoring and when program costs are offset by decreased acute utilization and improved medication persistence.

The methodology and protocol described here offer an actionable blueprint that pharmacies can adapt to their context—urban or rural, high- or low-resource. Mixed-methods evaluation, anchored in pragmatic trial design and implementation science metrics, ensures that effectiveness, usability, and feasibility are measured alongside clinical outcomes. Future work should compare device classes head-to-head, validate algorithms for trend-aware thresholds across diverse populations, and quantify long-term outcomes (e.g., cardiovascular events) and net costs. Partnerships among pharmacies, physicians, payers, and technology vendors—centered on patient choice and privacy—will be essential to translate pilot success into durable, population-level benefit.

References

- *Gupta, S. K. (2022). Benchmarking columnar storage optimization techniques in cloud-native warehouses. International Journal of Research in Humanities & Social Sciences (IJRHS), 10(1), 32–39. https://doi.org/10.63345/ijrhs.net.v10.i1.1*
- *Bharucha, S. (2019, November 23). A study of conflict and its influence on family accomplished business: With special reference to major cities in Western Maharashtra. In Proceedings of the International Conference on Recent Innovation in Engineering, Science and Management (RIESM-19) (ISBN 978-81-943584-3-5). Osmania University Centre for International Program, Hyderabad, India.*
- *Gupta, S. K. (2022). Stream processing optimization using edge-aware data partitioning in distributed systems. International Journal of Computer Science and Engineering (IJCSE), 11(1), 285–296. https://www.iaset.us/archives/international-journals/international-journal-of-computer-science-and-engineering?page=18*
- *Bharucha, S., & Kumar, D. (2020). To study about the family business association and conflict. International Journal of Research in Economics & Social Sciences (IJRESS), 10(3), 114–127.*
- *Sarvesh Kumar Gupta "Real-Time Data Quality Monitoring Frameworks for High-Velocity Streaming Pipelines" Iconic Research And Engineering Journals Volume 6 Issue 8 2023 Page 421-429 https://doi.org/10.64388/IREV6I8-1719275*
- *Saini, V. K., Bharucha, S., Kumar, A., & Rana, P. (2025). Strategic horizons: Leading with vision in a changing world. Yashita Prakashan Private Limited.*
- *Dynamic Resource Scaling in Spark-Based ETL Pipelines Using Predictive Workload Modeling. (2023). Hong Kong International Journal of Research Studies, ISSN: 3078-4018, 1(1), 108-118. https://doi.org/10.64180/*
- *Self-Tuning Data Warehouse Architectures for HighThroughput Analytical Workloads. (2023). International Journal of Engineering Fields, ISSN: 3078-4425, 1(1), 51-59.*
- *Joshi, J., Bharucha, S., Jadhav, D. R. R., & Rastogi, M. (2025). Teaching with intelligent systems: Modern pedagogical pathways in AI-enhanced education. Wissira Research Lab. https://doi.org/10.63345/book.wrl.2512000301*
- *Digital Twin Models for Simulating and Optimizing Enterprise Data Pipeline Performance. (2024). AI Tech International Journal, ISSN: 3079-4749, 2(2), 71-82. https://techaijournal.com/index.php/AIjournal/article/view/39*
- *Gupta, S. K. (2023). Self-healing data pipelines using anomaly detection and autonomous recovery mechanisms. International Journal of Research in All Subjects in Multi Languages*

(IJRSML), 11(10), 54–61. https://doi.org/10.63345/ijrsml.v11.i10.1

- *Sarvesh Kumar Gupta. (2024). Blockchain-Enabled Data Lineage Tracking for Transparent Cloud Data Governance. Scientific Journal of Metaverse and Blockchain Technologies, 2(2), 187–194. https://doi.org/10.36676/sjmbt.v2.i2.49*
- *Sarvesh Kumar Gupta. (2024). Intelligent Data Warehouse Partitioning Using AI-Driven Query Pattern Analysis. Modern Dynamics: Mathematical Progressions, 1(2), 540–547. https://doi.org/10.64170/mdmp.v1.i2.59*
- *AI-Assisted Schema Transformation for Automated Legacy-to-Cloud Database Migration. (2026). Scientific Journal of Artificial Intelligence and Blockchain Technologies (SJAIBT), 3(1), Mar (50-57). https://doi.org/10.63345/sjaibt.v3.i1.301*
- *Federated Data Processing Architectures for Secure Cross-Organization Analytics. (2026). World Journal of Future Technologies in Computer Science and Engineering (WJFTCSE) U.S. ISSN: 3070-6203, 2(2), May (60-68). https://doi.org/10.63345//wjftcse.v2.i2.201*
- *Sarvesh Kumar Gupta. (2025). Secure Data Migration Strategies on AWS Cloud. International Journal of Computational and Experimental Science and Engineering, 11(3). https://doi.org/10.22399/ijcesen.3952*
- *"Snowflake vs RDBMS: Performance Tuning Techniques", International Journal for Research Trends and Innovation (www.ijrti.org), ISSN:2456-3315, Vol.10, Issue 5, page no.c825-c832, May-2025, Available :http://www.ijrti.org/papers/IJRTI2505296.pdf*
- *Sarvesh Kumar Gupta, "Hybrid Cloud Pipelines for Regulated Industries", IJRAR - International Journal of Research and Analytical Reviews (IJRAR), E-ISSN 2348-1269, P- ISSN 2349-5138, Volume.12, Issue 2, Page No pp.705-712, May 2025, Available at : http://www.ijrar.org/IJRAR25B4662.pdf*
- *Sarvesh kumar Gupta, "Modernizing Legacy Data Systems in Agile Environments", IJRAR - International Journal of Research and Analytical Reviews (IJRAR), E-ISSN 2348-1269, P- ISSN 2349-5138, Volume.12, Issue 2, Page No pp.713-721, June 2025, Available at : http://www.ijrar.org/IJRAR25B4663.pdf*
- *Sarvesh Kumar Gupta, 2025. "Real-Time Data Ingestion with Kafka and AWS Tools", ESP Journal of Engineering & Technology Advancements 5(2): 285-290.*
- *Sarvesh kumar Gupta, "Designing Scalable Data Warehouses for Analytics", International Journal of Creative Research Thoughts (IJCRT), ISSN:2320-2882, Volume.13, Issue 7, pp.h868-h876, July 2025, Available at :http://www.ijcrt.org/papers/IJCRT2507898.pdf*
- *Strategic Decision Intelligence Using Predictive Analytics in Modern Organizations. (2026). Global Journal of Innovative Research Perspectives (GJIRP), 2(2), May (1-8). https://doi.org/10.63345/gjirp.v2.i2.201*
- *Sarvesh kumar Gupta. Best practices for oracle to PostgreSQL migration. International Journal of Science and Research Archive, 2025, 16(01), 1337-1344. Article DOI: https://doi.org/10.30574/ijsra.2025.16.1.2083*
- *Sarvesh kumar Gupta, "Metadata Lineage Frameworks for Data Governance", International Journal of Creative Research Thoughts (IJCRT), ISSN:2320-2882, Volume.13, Issue 9, pp.c895-c903, September 2025, Available at :http://www.ijcrt.org/papers/IJCRT2509332.pdf*
- *Gupta, S. K. (2025). Machine Learning Integration in Spark-Based Pipelines. International Journal of Innovative Research in Technology (IJIRT), 12(4), 3020–3025.*
- *Sarvesh Kumar Gupta, 2025. "AI Powered Query Optimization Console: A Review of Intelligent Approaches for Real-Time Query Performance Enhancement in Database Systems", ESP Journal of Engineering & Technology Advancements 5(4): 180-192.*
- *Bharucha, S. (2026). Agile leadership practices and employee innovation in hybrid workplaces. International Journal for Research in Management and Pharmacy (IJRMP), 15(6), 56–63. https://doi.org/10.63345/ijrmp.v15.i6.1*
- *Sarvesh Kumar Gupta. Cloud ETL optimization with AWS glue and spark. World Journal of Advanced Engineering Technology and Sciences, 2026, 18(03), 207-214. Article DOI: https://doi.org/10.30574/wjaets.2026.18.3.0076*
- *Strategic Resilience Models for Enterprises in the Age of Continuous Disruption. (2026). E-Journal of Science and Emerging Technologies (EJSET), 2(2), May (26-33). https://doi.org/10.63345/ejset.v2.i2.201*
- *Bharucha, S. (2023). Digital legacy and innovation balance in family-owned enterprises. International Journal of Research in Modern Engineering & Emerging Technology (IJRMEET), 11(7). https://doi.org/10.63345/ijrmeet.org.v11.i7.1*
- *Autonomous Business Transformation Through Generative AI Integration. (2026). Global Journal of Innovative Research Perspectives (GJIRP), 2(2), Apr (83-91). https://doi.org/10.63345/gjirp.v2.i2.101*
- *Bharucha, S. (2023). Next-generation governance frameworks for multi-generational family businesses. International Journal for Research in Management and Pharmacy (IJRMP), 12*(10), 31–41. https://doi.org/10.63345/ijrmp.v12.i10.5*
- *Strategic Leadership for Hybrid Human–AI Workforce. (2025). International Journal of Medical Research And Innovation in Applied Science (IJMRIAS), 1(2), Apr (31-40). https://doi.org/10.63345/ijmrias.v1.i2.101*

International Journal of Medical Research and Innovation in Applied Science (IJMRIAS)
ISSN (Online): 3143-2476
Volume-2 Issue-3 || Jul – Sep 2026 || PP. 7 – 16 https://ijmrias.org/

- *Bharucha, S. (2022). Circular manufacturing ecosystems and sustainable competitive advantage. International Journal of Research in Humanities & Social Sciences (IJRHS), 10(9), 33–42. https://doi.org/10.63345/ijrhs.net.v10.i9.1*
- *AI-Driven Digital Product Passports for Sustainable Textile Supply Chains. (2025). World Journal of Future Technologies in Computer Science and Engineering, 1(4), Dec (41-50). https://doi.org/10.63345/wjftcse.v1.i4.301*
- *Bharucha, S. (2022). Predictive restructuring frameworks for organizational renewal. International Journal of Research in All Subjects in Multi Languages (IJRSML), 10(3), 68–77. https://doi.org/10.63345/ijrsml.v10.i3.1*
- *Bharucha, S. (2024). Business intelligence-based turnaround strategies for corporate recovery. International Journal for Research in Education (IJRE), 13 (8), 10–19. https://doi.org/10.63345/ijre.v13.i8.1*
- *Generative AI and the Reinvention of Management Education. (2026). Scientific Journal of Artificial Intelligence and Blockchain Technologies (SJAIBT), 1(2), Jun (1-9). https://doi.org/10.63345/sjaibt.v1.i2.301*